Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 17/20 | 0.43 |
| ▸ | RARA | P10276 | 15/20 | 0.43 |
| ▸ | RARG | P13631 | 15/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4497874 | 1.00 | RARB (0.43) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4509114 | 0.92 | RARB (0.42) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4509112 | 0.92 | RARB (0.42) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4506849 | 0.83 | RARB (0.46) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4506857 | 0.83 | RARB (0.46) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4497873 | 0.81 | RARB (0.41) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4491751 | 0.81 | RARB (0.48) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4508557 | 0.77 | RARB (0.44) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4494180 | 0.77 | RARB (0.44) | RARBRARARARGRXRANR2E1 | |
| SCHEMBL4494185 | 0.77 | RARB (0.44) | RARBRARARARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592478-B2 | Ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-09-22 | — | — | US | disclosed |
| US-20080213347-A1 | Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213347-A1 | Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof | RARB, RARG, RARA | RARB 1/4885RARA 3/4885RARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.